Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

Published:2012-12-07 Issue:5 Volume:207 Page:740-748
ISSN:1537-6613
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:

Author:

Eron Joseph J.¹,Clotet Bonaventura²,Durant Jacques³,Katlama Christine⁴,Kumar Princy⁵,Lazzarin Adriano⁶,Poizot-Martin Isabelle⁷,Richmond Gary⁸,Soriano Vincent⁹,Ait-Khaled Mounir¹⁰,Fujiwara Tamio¹¹,Huang Jenny¹²,Min Sherene¹³,Vavro Cindy¹³,Yeo Jane¹⁰,Walmsley Sharon L.,Cox Joseph,Reynes Jacques,Morlat Philippe,Vittecoq Daniel,Livrozet Jean-Michel,Fernández Pompeyo Viciana,Gatell Jose M.,DeJesus Edwin,DeVente Jerome,Lalezari Jacob P.,McCurdy Lewis H.,Sloan Louis A.,Young Benjamin,LaMarca Anthony,Hawkins Trevor,

Affiliation:

1. Infectious Diseases Division, School of Medicine, University of North Carolina, Chapel Hill

2. Hospital Germans Trias i Pujol, Irsicaixa Foundation, Barcelona, France

3. Hôpital de l'Archet 1, Nice, France

4. Hôpital de la Pitié-Salpêtrière, Paris VI University, Paris, France

5. Georgetown University, Washington, D.C.

6. San Raffaele Scientific Institute, Milan, Italy

7. APHM Sainte-Marguerite, Aix Marseille University, Marseille, France

8. Broward Health, Fort Lauderdale, Florida

9. Hospital Carlos III, Madrid, Spain

10. GlaxoSmithKline, London, United Kingdom

11. Shionogi & Co Ltd, Osaka, Japan

12. GlaxoSmithKline, Toronto, Canada

13. GlaxoSmithKline, Research Triangle Park, North Carolina

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Link

http://academic.oup.com/jid/article-pdf/207/5/740/18068550/jis750.pdf

Reference20 articles.

1. Integrase inhibitors in the treatment of HIV-1 infection;Powderly;J Antimicrob Chemother,2010

2. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study;Markowitz;J Acquir Immune Defic Syndr,2007

3. Raltegravir with optimized background therapy for resistant HIV-1 infection;Steigbigel;N Engl J Med,2008

4. Patterns of resistance development with integrase inhibitors in HIV;Mbisa;Infect Drug Resist,2011

5. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients;DeJesus;J Acquir Immune Defic Syndr,2006

Cited by 267 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Case of Dolutegravir Plus Darunavir Antiretroviral Regimens: Is It Always Useful to Double the Drug Doses? A Short Communication;Therapeutic Drug Monitoring;2024-09-05

2. Integrated Population Exposure–Response of Dolutegravir in HIV‐1 Supports Bridging of Clinical Response Influenced by Relevant Intrinsic and Extrinsic Patient Characteristics;Clinical Pharmacology & Therapeutics;2024-07-16

3. Population Pharmacokinetic Analysis of Dolutegravir in Treatment‐Experienced Adults Living with HIV‐1;The Journal of Clinical Pharmacology;2024-07-16

4. Clinical Profile and Adverse Effects of Dolutegravir Treatment in HIV-Positive Patients: A Prospective Observational Study;Cureus;2024-06-17

5. Dolutegravir induces FOLR1 expression during brain organoid development;Frontiers in Molecular Neuroscience;2024-05-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3